Ultragenyx Expands Leadership Team and Appoints Ernie Meyer as Chief Human Resources Officer
September 01 2020 - 8:31AM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
products for serious rare and ultra-rare genetic diseases, today
announced that it has appointed Ernie Meyer as Executive Vice
President and Chief Human Resources Officer, effective September 1,
2020. In this newly created role, Mr. Meyer will lead all aspects
of the Global Human Resources and Facilities operations. He will
report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx’s Chief Executive
Officer, and will serve on the Executive Leadership
Team.
“Ernie has tremendous experience building multi-national
biopharmaceutical organizations, and his leadership will be key to
the continued growth and development of our excellent team as we
enter the next chapter of our future,” said Dr. Kakkis. “We welcome
him to Ultragenyx and look forward to his contributions to help us
achieve our goals as we begin our second decade as a diversified,
global rare disease company.”
Mr. Meyer joins Ultragenyx from Portola Pharmaceuticals, where
he was Executive Vice President, Chief Human Resources Officer
since 2018. Before Portola, he spent more than 13 years at Celgene,
most recently as Executive Vice President of Human Resources and
Corporate Services. While at Celgene, he played a significant role
in the company’s growth to more than 7,000 employees in 37
countries. Prior to Celgene, Mr. Meyer spent 10 years at Motorola
in a variety of human resource roles of increasing scope and
responsibility. Mr. Meyer holds a B.S. in Business Management with
a concentration in Management Information Systems from Widener
University.
“Ultragenyx is making great strides in the rare disease space
and places tremendous focus on people – from patients and the rare
disease community it serves, to the employees who make Ultragenyx
the special company that it is,” said Mr. Meyer. “I am delighted to
have the opportunity to join the leadership team to foster and
develop these strengths, and to contribute to the meaningful work
the organization is doing on behalf of patients.”
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing
to patients novel products for the treatment of serious rare and
ultra-rare genetic diseases. The company has built a diverse
portfolio of approved therapies and product candidates aimed at
addressing diseases with high unmet medical need and clear biology
for treatment, for which there are typically no approved therapies
treating the underlying disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s
website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.Investors &
MediaJoshua Higa(415) 475-6370
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Apr 2024 to May 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From May 2023 to May 2024